Sava Technologies Ltd., the London-based startup pioneering real-time molecular health monitoring, today announced £14 million in Series A funding, following promising early results from its clinical trial. The round was led by Balderton Capital and Pentland Ventures, with strong participation from new investors Norrsken VC and JamJar Investments. They were joined by other investors including True, Italian Founders Fund, Athletico Ventures, SOLO Investments and Exceptional Ventures. The round will help Sava accelerate regulatory approval and commercialisation of its next-generation wearable.
Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, Sava’s mission is to build the technological foundation for preventative and personalised healthcare. The team has developed a multi-molecule biosensor capable of detecting biomarkers just beneath the skin, in real-time. This proprietary technology is powering their first product – a pain-free CGM that streamlines molecular insights in real-time to your phone, at a fraction of the cost of current alternatives.
Sava’s latest clinical trial, conducted independently by third-party investigators across sites in Oxford and Cambridge, involves 50 patients with Type 1 and insulin-dependent Type 2 diabetes.
Early results from the first 25 patients showed Sava’s proprietary technology delivered reliable, accurate glucose readings for up to 10 days of continuous wear - a milestone no other microsensor platform has been able to achieve to date. Most microsensor systems fail to last 5 days, and many struggle beyond 24 hours. The trial, designed in collaboration with leading diabetes clinicians and regulators, provides a critical foundation for future regulatory submissions and Sava’s pivotal study, set to launch in the coming year.
Today, only 1% of people with diabetes use CGMs, yet this group generates over £8.5bn in annual sales, growing 10% year-on-year. Existing devices are often painful, expensive, and inaccessible. Sava’s device promises to transform diabetes care and expand adoption of CGMs by offering a pain-free, cost-effective and highly scalable alternative.
While tracking glucose is the first use case, Sava’s modular, multi-analyte sensing platform is capable of detecting additional molecules, providing users with the ability to unobtrusively monitor multiple biomarkers in real-time, paving the way for a future of preventative and personalised health. With interest growing among athletes and health-conscious consumers, Sava is well-positioned to tap into the global wearables market, which is projected to exceed £75bn by 2029.
This latest round brings Sava’s total funding to £24m, with backing from leading VCs, returning angel investors, along with funding from the EU and UK Government.
Sava’s team has rapidly grown to over 60+ people, including experts behind market-leading CGMs. The new capital will be used to further expand Sava’s world-leading team, advance automated manufacturing capabilities to reach target launch volumes, and accelerate the clinical validation of its microsensor technology.
